Dr Mir Shahnawaz, founder of DERMIS, recently discussed advances in treating atopic dermatitis at the RAD Symposium in Jaipur. India’s top dermatologists attended the event, which focused on groundbreaking developments in skin health and innovative treatments. A key highlight was the discussion on Abrocitinib, a JAK1 inhibitor, which has shown promising results for treating moderate to severe atopic dermatitis.
Atopic dermatitis, commonly known as eczema, is a chronic skin condition that causes red, scaly rashes and dry, itchy skin. For some individuals, a genetic mutation disrupts the skin’s ability to act as a protective barrier. Dr Mir Shahnawaz emphasised the importance of addressing the root cause of atopic dermatitis and how Abrocitinib offers a new treatment path.
Features of Abrocitinib
- Abrocitinib is an oral medication available in various dosage options, providing flexibility for treatment plans.
- It stands out due to its low frequency of adverse effects, making it a well-tolerated option for many patients.
- Clinical studies show that Abrocitinib is significantly more effective than a placebo in reducing the extent of eczema, inflammation, and itching.
Benefits of Abrocitinib
- Abrocitinib provides rapid relief from itching, often showing noticeable improvement as early as day one of treatment.
- The medication works by inhibiting neuronal JAK1 pathways linked to pruritus, offering a targeted approach to managing atopic dermatitis.
- Abrocitinib is less likely to trigger an immunogenic response than traditional biologic treatments, enhancing its appeal.
Dr Mir shared valuable insights into the clinical potential of Abrocitinib and its impact on patients’ prognosis.
Expanding applications of Abrocitinib
As more clinicians adopt Abrocitinib, its affordability and accessibility are likely to improve, making it a mainstream treatment option for dermatology practices worldwide. Pharmaceutical advancements may lead to extended-release versions or combination therapies, boosting the drug’s clinical utility and improving patient adherence.
As dermatology continues to embrace such innovations, Abrocitinib could play a key role in transforming the management of moderate to severe atopic dermatitis globally.
Reference link: https://www.greaterkashmir.com/kashmir/renowned-dermatologist-delivers-presentation-at-rad-symposium-in-jaipur/